Anaphylm Hit by FDA Complete Response Letter; Aquestive Reports 23% Revenue Drop
summarizeSummary
Aquestive Therapeutics received a Complete Response Letter (CRL) from the FDA for its Anaphylm drug candidate, citing packaging and administration issues that require revisions and additional studies. Concurrently, the company reported a 23% revenue drop to $44.5 million in 2025, alongside an $83.8 million net loss. This news follows the company's 10-K filing yesterday, which disclosed a significant increase in net loss for 2025 and a major FDA approval delay for Anaphylm. The current report provides critical specifics, detailing the CRL and the exact financial figures. The CRL with specific issues requiring further studies significantly prolongs the development timeline and increases costs for Anaphylm, a key drug candidate. This, combined with the substantial revenue decline and net loss, paints a challenging financial and operational picture for the company. Investors will be closely watching for Aquestive's revised strategy and timeline for addressing the FDA's concerns and resubmitting the Anaphylm NDA, as well as any further updates on its financial performance and capital needs.
At the time of this announcement, AQST was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $524M. The 52-week trading range was $2.12 to $7.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.